Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $205.00 | Equal Weight → Overweight | Barclays |
| 3/21/2025 | $260.00 | Neutral → Buy | Goldman |
| 3/14/2025 | $260.00 | Hold → Buy | Stifel |
| 2/3/2025 | Outperform → Mkt Perform | Raymond James | |
| 12/23/2024 | Sector Perform | Scotiabank | |
| 12/19/2024 | $275.00 | Buy | Guggenheim |
| 12/13/2024 | $290.00 | Neutral → Buy | BofA Securities |
| 10/31/2024 | $285.00 | Peer Perform → Outperform | Wolfe Research |
11-K - DANAHER CORP /DE/ (0000313616) (Filer)
SD - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
3 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i
WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f
WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You
Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00
Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00
Stifel upgraded Danaher from Hold to Buy and set a new price target of $260.00
WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You
WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and h
WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-
WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i
WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)